Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models
Scientist.com, the leading R&D procurement orchestration platform for the life sciences, today announced a major expansion of its Tumor Model Finder (TMF) following a strategic partnership with XenoSTART, a global leader in patient-derived xenograft (PDX) model development and testing. The addition of hundreds of unique and high-demand XenoSTART models pushes the TMF past a milestone of 10,000 searchable oncology models, giving cancer researchers unprecedented access to diverse and clinically relevant tools.
'Pharma discovery teams often face critical delays accessing translational research partners with deeply characterized PDX models that accurately reflect real-world patient disease complexity,' said Michael J. Wick, PhD, Chief Scientific Officer at XenoSTART. 'By joining the Scientist.com marketplace, XenoSTART eliminates this significant barrier, providing immediate access to our highly relevant, patient-derived tumor models that are directly linked to our global clinical network. This integration empowers drug developers to confidently accelerate therapeutic decision-making and precisely guide their translational strategies—ultimately speeding effective cancer treatments to patients.'
Scientist.com's Tumor Model Finder is a centralized, AI-powered platform that aggregates and standardizes tumor model data from 20+ leading CROs. It allows researchers to search, compare, and source PDX, CDX, organoid, and cell line models—spanning 17 cancer types—through a single workflow. The platform also includes drug response profiles, genomic alterations (e.g., KRAS, BRAF mutations), and RNA seq-based gene expression data to support informed model selection and study design.
'XenoSTART's contribution significantly boosts the depth and quality of our TMF offerings,' said Javier Pineda, PhD, Director of Preclinical AI at Scientist.com. 'Researchers can now find models with richer data and greater relevance to their specific cancer studies.'
This collaboration also highlights the translational impact of START's global research ecosystem. With patient-derived tissue samples sourced from START's expansive oncology trial network, XenoSTART's models provide critical continuity between preclinical evaluation and clinical trial execution—helping pharmaceutical companies make faster, more confident decisions in oncology drug development.
To learn more or schedule a demo of the Tumor Model Finder, email [email protected].
About Scientist.com
Scientist.com is the life-science industry's premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world's top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on Scientist.com to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Visit Scientist.com to discover how we accelerate science.
About XenoSTART
Founded in 2007, XenoSTART is a translational research organization dedicated to advancing oncology drug development through clinically relevant preclinical cancer models. The XenoSTART Patient-Derived Xenograft (XPDX) platform features more than 2,800 models across a broad range of tumor types and disease stages sourced from patients treated at START's domestic and international cancer centers. Models are deeply characterized using histologic analysis, DNA/RNA sequencing, and in vivo drug sensitivity testing, and are clinically annotated with the donor patient's treatment history and clinical outcome. By bridging real-world tumor biology with rigorous preclinical science, XenoSTART enables pharmaceutical partners to make smarter, faster decisions from bench to bedside. Learn more about XenoSTART at https://startresearch.com/preclinical/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250723028694/en/
CONTACT: Scientist.com
Sean Preci
+1 877-644-3044
[email protected]
XenoSTART
Lauren Panco
609-216-4920
KEYWORD: EUROPE UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: OTHER HEALTH RESEARCH PHARMACEUTICAL ONCOLOGY TECHNOLOGY ARTIFICIAL INTELLIGENCE GENETICS HEALTH TECHNOLOGY SCIENCE BIOTECHNOLOGY OTHER SCIENCE HEALTH
SOURCE: Scientist.com
Copyright Business Wire 2025.
PUB: 07/23/2025 07:55 AM/DISC: 07/23/2025 07:55 AM
http://www.businesswire.com/news/home/20250723028694/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 minutes ago
- Associated Press
Rosen Law Firm Encourages Tungray Technologies Inc Investors to Inquire About Securities Class Action Investigation
NEW YORK, July 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tungray Technologies Inc (NASDAQ: TRSG) resulting from allegations that Tungray Technologies may have issued materially misleading business information to the investing public. So What: If you purchased Tungray Technologies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: On December 31, 2024, Tungray Technologies filed a current report with the U.S. Securities and Exchange Commission on Form 6-K. The current report stated that on 'December 30, 2024, the Board of Directors of Tungray Technologies Inc (the 'Company'), upon recommendation of the Audit Committee and following discussions with management, determined that the Company's financial statements for the years ended December 31, 2023, 2022 and 2021 included in the Company's Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on April 26, 2024 (the '20-F'), should no longer be relied upon. Similarly, related reports, press releases, earnings releases, and investor communications describing the Company's financial statements for these periods should no longer be relied upon.' Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] View original content to download multimedia: SOURCE THE ROSEN LAW FIRM, P. A.
Yahoo
30 minutes ago
- Yahoo
Markel Group reports 2025 second quarter and six-months results
RICHMOND, Va., July 30, 2025 /PRNewswire/ -- Markel Group Inc. (NYSE:MKL) today reported its financial results for the second quarter of 2025. The Company also announced today it filed its Form 10-Q for the quarter ended June 30, 2025 with the Securities and Exchange Commission. "We've made meaningful changes across our business in recent years, all with the goal of consistently compounding your capital," said Tom Gayner, Chief Executive Officer of Markel Group. "Our results included $1.4 billion in operating income through the first half of the year. Also, this quarter, we took another step to simplify the structure of our insurance business by placing reinsurance into run-off. That decision enables the team to focus more clearly on the core underwriting activities where we have distinct strengths." The following table presents the Company's summary financial data, by engine, for the quarters and six months ended June 30, 2025 and Ended June 30, Six Months Ended June 30, (dollars in thousands, except per share amounts) 2025202420252024 Operating revenues:Insurance $ 2,232,067$ 2,148,268$ 4,419,880$ 4,333,986 Investments:Net investment income 228,126220,454463,727437,658 Net investment gains (losses) 580,223(130,017)431,152772,264 Other 14,0649,3579,45430,203 Total Investments 822,41399,794904,3331,240,125 Markel Ventures 1,548,2861,453,7812,677,6582,594,387 Total operating revenues $ 4,602,766$ 3,701,843$ 8,001,871$ 8,168,498 Operating income:Insurance (1) $ 128,412$ 176,925$ 273,448$ 312,750 Investments:Net investment income 228,126220,454463,727437,658 Net investment gains (losses) 580,223(130,017)431,152772,264 Other 14,0649,3579,45430,203 Total Investments 822,41399,794904,3331,240,125 Markel Ventures 207,728177,498310,238281,413 Consolidated segment operating income (2) 1,158,553454,2171,488,0191,834,288 Amortization of acquired intangible assets (51,213)(44,237)(98,155)(88,522) Total operating income $ 1,107,340$ 409,980$ 1,389,864$ 1,745,766 Comprehensive income to shareholders $ 867,511$ 244,356$ 1,215,181$ 1,152,741 Diluted net income per common share $ 49.67$ 18.62$ 61.60$ 94.24 Markel Insurance combined ratio 96.9 %93.8 %96.5 %94.5 % (1) See "Supplemental Financial Information" for the components of our Insurance engine operating income. (2) See "Non-GAAP Financial Measures" for additional information on this non-GAAP measure. Highlights of results from the quarter and six months: The changes in operating revenues and operating income for both the quarter and six months ended June 30, 2025 were largely driven by market value movements within our equity portfolio. Generally accepted accounting principles (GAAP) require that we include unrealized gains and losses on equity securities in net income. This may lead to short-term volatility in revenues and operating income that temporarily obscures our underlying operating performance. Net investment income increased 3% and 6% for the quarter and six months ended June 30, 2025, respectively, reflecting a higher yield and higher average holdings of fixed maturity securities in 2025. Markel Ventures operating revenues and operating income for the quarter and six months ended June 30, 2025 increased, reflecting contributions from the acquisitions of Valor and EPI, as well as improved performance at our construction services businesses. The increase in Markel Insurance's combined ratio for the quarter ended June 30, 2025 was primarily driven by adverse development in 2025 on our run-off risk-managed directors and officers product lines and on the Global Reinsurance division, which we announced is being placed into run-off. This adverse development in the second quarter of 2025 resulted in less overall net favorable development on prior accident years loss reserves in the second quarter of 2025 compared to the second quarter of 2024. Underwriting results for the first half of 2025 included $60.9 million of net losses and loss adjustment expenses, or one-and-a-half points on the Markel Insurance combined ratio, attributed to the January 2025 wildfires in southern California (California Wildfires) compared to no catastrophe losses in the first half of 2024. Excluding losses attributed to the California Wildfires, the Markel Insurance combined ratio in the first half of 2025 was consistent with the same period of 2024. We believe our financial performance is most meaningfully measured over longer periods of time, which tends to mitigate the effects of short-term volatility and also aligns with the long-term perspective we apply to operating our businesses and making investment decisions. The following table presents a long-term view of our Months Ended June 30, Years Ended December 31, (dollars in thousands) 20252024202320222021 Operating income (loss):Insurance (1) $ 273,448$ 601,002$ 348,145$ 928,709$ 718,800 Investments (2) 904,3332,772,9502,241,419(1,167,548)2,353,124 Markel Ventures 310,238520,082519,878404,281330,120 Consolidated segment operating income (3) 1,488,0193,894,0343,109,442165,4423,402,044 Amortization and impairment (98,155)(181,472)(180,614)(258,778)(160,539) Total operating income (loss) $ 1,389,864$ 3,712,562$ 2,928,828$ (93,336)$ 3,241,505 Net investment gains (losses) (2) $ 431,152$ 1,807,219$ 1,524,054$ (1,595,733)$ 1,978,534 Compound annual growth rate in closing stock price per share from December 31, 2020 to June 30, 2025 16 % (1) See "Supplemental Financial Information" for the components of our Insurance engine operating income. (2) Investments engine operating income includes net investment gains (losses), which are primarily comprised of unrealized gains and losses on equity securities. (3) See "Non-GAAP Financial Measures" for additional information on this non-GAAP measure. ******** A copy of our Form 10-Q is available on our website at under Investor Relations-Financials, or on the SEC website at Readers are urged to review the Form 10-Q for a more complete discussion of our financial performance. Our quarterly conference call, which will involve discussion of our financial results and business developments and may include forward-looking information, will be held Thursday, July 31, 2025, beginning at 9:30 a.m. (Eastern Time). Investors, analysts and the general public may listen to the call via live webcast at The call may be accessed telephonically by dialing (888) 660-9916 in the U.S., or (646) 960-0452 internationally, and providing Conference ID: 4614568. A replay of the call will be available on our website approximately one hour after the conclusion of the call. Any person needing additional information can contact Markel Group's Investor Relations Department at IR@ Supplemental Financial InformationThe following table presents the components of our Insurance engine operating Ended June 30, Six Months Ended June 30, Years Ended December 31, (dollars in thousands) 20252024202520242024202320222021 Markel Insurance segment $ 60,337$ 123,896$ 136,619$ 218,624$ 374,223$ 101,432$ 600,087$ 603,450 Other insurance operations 68,07553,029136,82994,126226,779246,713328,622115,350 Insurance $ 128,412$ 176,925$ 273,448$ 312,750$ 601,002$ 348,145$ 928,709$ 718,800 Non-GAAP Financial MeasuresConsolidated segment operating income is a non-GAAP financial measure as it represents the total of the segment operating income from each of our operating segments and excludes items included in operating income. Consolidated segment operating income excludes amortization of acquired intangible assets and goodwill impairments arising from purchase accounting as they do not represent costs of operating the underlying businesses. The following table reconciles operating income to consolidated segment operating Ended June 30, Six Months Ended June 30, Years Ended December 31, (dollars in thousands) 20252024202520242024202320222021 Operating income (loss) $ 1,107,340$ 409,980$ 1,389,864$ 1,745,766$ 3,712,562$ 2,928,828$ (93,336)$ 3,241,505 Amortization of acquired intangible assets 51,21344,23798,15588,522181,472180,614178,778160,539 Impairment of goodwill ——————80,000— Consolidated segment operating income $ 1,158,553$ 454,217$ 1,488,019$ 1,834,288$ 3,894,034$ 3,109,442$ 165,442$ 3,402,044 About Markel GroupMarkel Group Inc. is a diverse family of companies that includes everything from insurance to bakery equipment, building supplies, houseplants, and more. The leadership teams of these businesses operate with a high degree of independence, while at the same time living the values that we call the Markel Style. Our specialty insurance business sits at the core of our company. Through decades of sound underwriting, the Markel Insurance team has provided the capital base from which we built a system of businesses and investments that collectively increase Markel Group's durability and adaptability. It's a system that provides diverse income streams, access to a wide range of investment opportunities, and the ability to efficiently move capital to the best ideas across the company. Most importantly though, this system enables each of our businesses to advance our shared goal of helping our customers, associates, and shareholders win over the long term. Visit to learn more. Cautionary StatementCertain of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Statements that are not historical facts, including statements about our beliefs, plans or expectations, are forward-looking statements. These statements are based on our current plans, estimates and expectations. There are risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by such statements. Factors that may cause actual results to differ are often presented with the forward-looking statements themselves. Additional factors that could cause actual results to differ from those predicted are set forth in our Annual Report on Form 10-K for the year ended December 31, 2024, including under "Business Overview," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Safe Harbor and Cautionary Statement," and "Quantitative and Qualitative Disclosures About Market Risk," and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, including under "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Safe Harbor and Cautionary Statement," "Quantitative and Qualitative Disclosures About Market Risk," and "Risk Factors." We assume no obligation to update this release (including any forward-looking statements) as a result of new information, developments, or otherwise. This release speaks only as of the date issued. View original content to download multimedia: SOURCE Markel Group Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Equinix raises annual results forecast on steady data center demand
(Reuters) -Data center firm Equinix raised its forecast for annual results on Wednesday, signaling steady demand from its enterprise customers investing in AI solutions. The company has benefited from the increased demand for data center infrastructure amid a surge in artificial intelligence usage. Major cloud firms, including Google, have pledged significant investments this year to expand on AI, underscoring robust demand for AI-related products and solutions. Equinix provides organizations with secure, resilient and power-efficient environments to house their IT equipment within its data centers, while offering shared infrastructure and connectivity solutions. The company now expects annual revenue to be between $9.23 billion and $9.33 billion, compared with prior projection of $9.18 billion to $9.28 billion. It now expects annual per-share funds from operations, a key measure of cash flow, to be in the range of $37.67 to $38.48 per share, compared with previous forecast of $37.36 to $38.17. In the second quarter ended June 30, the company's revenue rose 4.6% to $2.26 billion, in line with estimates, according to data compiled by LSEG. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
